We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Generic problem

26 April 2012 By Quentin Webb

Singlehandedly funding the 2007 buyout of Actavis, an Icelandic drugmaker, was one of Deutsche Bank’s worst boom-era moves. Failed M&A rescues, restructuring and $1.7 bln of charges followed. At least Watson Pharma is now ending this unhappy saga with a near-$6 bln takeover.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)